Appointments at Norgine, CDRD and Prometheus Laboratories – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Medicine

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Norgine, CDRD and Prometheus Laboratories.

Colleen Goggins ​is to retire as worldwide chairman, consumer group at Johnson & Johnson ​(J&J​). Goggins has held the position since 2001, and joined J&J in 1981, but is to retire next year after manufacturing problems at the consumer unit prompted the Tylenol recall.

Speciality pharma Norgine ​has named Rosemarie Corrigan ​as director of global quality. Corrigan has previously worked at Quintiles, Innovex and Stiefel Laboratories.

John Babcook ​has been hired to head up a new biologics unit at the Canadian Centre for Drug Research and Development ​(CDRD​). Before joining CDRD Babcook worked at Amgen. He has also co-founded ImmGenics.

BioProcess Technology Consultants​ has appointed Lars Skriver ​to lead operations at its new European office in Denmark. Skriver joined BioProcess two years ago having previously worked as director and principal consultant at L&K Biosciences.

Declan Doogan ​has joined Prometheus Laboratories ​as executive vice president (EVP) and chief medical officer. Doogan has more than 30 years of drug development experience from his time at Pfizer and most recently worked at Amarin.

Rapid Micro Biosystems ​has appointed Julie Sperry ​as chief commercial officer. Sperry has more than 30 years of experience in healthcare, pharma and manufacturing at companies including Thermo Fisher Scientific and Millipore.

Bruce Peacock ​has been named as a director at Discovery Labs​, expanding the company’s board to six members. In recent years Peacock has worked at SV Life Sciences Advisors and Alba Therapeutics. Earlier in his career Peacock worked at Cephalon and Centocor.

Ensemble Therapeutics ​has hired Ted Hibben ​as SVP of corporate development. Hibben has previously worked at Cequent Pharmaceuticals and Coley Pharmaceutical Group.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more